Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2024 Jan 26;15:1365827. doi: 10.3389/fimmu.2024.1365827

Corrigendum: Antimicrobial resistance in the COVID-19 landscape: is there an opportunity for anti-infective antibodies and antimicrobial peptides?

José M Pérez de la Lastra 1,*,, Uttpal Anand 2,*,, Sergio González-Acosta 1, Manuel R López 1, Abhijit Dey 3, Elza Bontempi 4, Antonio Morales delaNuez 1
PMCID: PMC10853875  PMID: 38343533

In the published article, there was an error in the affiliation information about Uttpal Anand [2]. Instead of “Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel”, it should be “CytoGene Research & Development LLP, Uttar Pradesh, India”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES